Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with rituximab and nilotinib

Overview of attention for article published in Bone Marrow Transplantation, March 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (76th percentile)
Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

twitter: 14 X users

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 23 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 22 X posts from 14 X users, with an upper bound of 38,806 followers.

@MediHumdani Agree with trying low dose IL-2. Logistics and approval may become challenge but not impossible. Not sure if this would be a good option but this is from Dutch group using Rituximab followed by Nilotinib https://t.co/PbjRqS9wKW

07 Aug 2020

Reply Repost Favourite

RT @British_SocBMT: https://t.co/yIpmNv7QRB

24 Nov 2018

Reply Repost Favourite

RT @British_SocBMT: https://t.co/yIpmNv7QRB

21 Nov 2018

Reply Repost Favourite

https://t.co/yIpmNv7QRB

21 Nov 2018

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 18 additional X posts.